Hormone-sensitive Prostate Cancer
📧 Sign up to get email alerts when something new happens for Hormone-sensitive Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-06-08Clinical Trial Update: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) [Phase 3]
Phase III trial evaluating 177Lu-PSMA-617 plus standard of care versus standard of care alone in metastatic hormone-sensitive prostate cance…
-
CLINICAL_TRIALS trial_result · 2026-04-23Clinical Trial Update: An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) [Phase 2]
Open-label Phase 2 study evaluating JSB462 (Luxdegalutamide) in combination with Abiraterone in adult men with metastatic hormone-sensitive …
-
CLINICAL_TRIALS trial_result · 2026-04-02Clinical Trial Update: A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study. [Phase 2]
A Phase 2 clinical trial evaluating darolutamide in combination with androgen deprivation therapy for metastatic hormone-sensitive prostate …
-
CLINICAL_TRIALS trial_result · 2026-03-31Clinical Trial Update: Evaluation of the Efficacy and Safety of Darolutamide + ADT Combined With Low-dose Docetaxel in mHSPC [Phase 2]
Phase 2 trial update evaluating the efficacy and safety of darolutamide plus androgen deprivation therapy with low-dose docetaxel in metasta…
-
CLINICAL_TRIALS trial_result · 2026-03-18Clinical Trial Update: PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.
This clinical trial update reports a completed study evaluating a PSMA PET/CT-based multimodal model to predict response to first-line thera…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-02-18Clinical Trial Update: A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer [Phase 1]
A Phase 1 clinical trial to evaluate the safety and drug levels of ASP5541 in Chinese participants with prostate cancer is currently recruit…
-
CLINICAL_TRIALS trial_result · 2025-05-29Clinical Trial Update: Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer [Phase 2]
A Phase 2 trial update reports completing the study investigating combining EPI-7386 with enzalutamide and androgen deprivation therapy in m…
-
CLINICAL_TRIALS trial_result · 2025-02-17Clinical Trial Update: A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients [Phase 3]
Phase 3 trial comparing Docetaxel 75 mg/m2 every 3 weeks versus 50 mg/m2 every 2 weeks, in combination with darolutamide and androgen depriv…
-
CLINICAL_TRIALS trial_result · 2024-11-21Clinical Trial Update: Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study
This completed DECIDER trial evaluated patient preferences for prostate cancer treatment attributes using a survey-based discrete choice exp…
-
CLINICAL_TRIALS trial_result · 2024-01-02Clinical Trial Update: The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC [Phase 2]
Phase 2 clinical trial update reporting on the safety and tolerability of GT0918 in patients with metastatic hormone-sensitive and castratio…
-
CLINICAL_TRIALS trial_result · 2023-11-18Clinical Trial Update: Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) [Phase 3]
Phase 3 trial evaluating pembrolizumab plus enzalutamide and ADT versus placebo plus enzalutamide and ADT in metastatic hormone-sensitive pr…
-
CLINICAL_TRIALS trial_result · 2023-11-18Clinical Trial Update: Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) [Phase 3]
This Phase 3 trial assesses pembrolizumab added to enzalutamide plus androgen deprivation therapy versus placebo added to enzalutamide plus …
-
CLINICAL_TRIALS trial_result · 2023-11-18Clinical Trial Update: An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) [Phase 3]
Phase 3 trial evaluating enzalutamide plus androgen deprivation therapy versus placebo plus ADT in Chinese men with metastatic hormone-sensi…
-
CLINICAL_TRIALS trial_result · 2023-11-07Clinical Trial Update: Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension [Phase 3]
Phase 3 China extension of KEYNOTE-991 assessed pembrolizumab plus enzalutamide plus androgen deprivation therapy vs placebo plus enzalutami…
-
CLINICAL_TRIALS trial_result · 2023-07-21Clinical Trial Update: Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC [Phase 3]
A Phase 3 clinical trial comparing a 6-month versus long-term course of Rezvilutamide with ADT and chemotherapy in metastatic hormone-sensit…
-
CLINICAL_TRIALS trial_result · 2023-02-24Clinical Trial Update: Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer [Phase 3]
Phase 3 trial evaluating darolutamide added to standard androgen deprivation therapy and docetaxel in metastatic hormone-sensitive prostate …
-
CLINICAL_TRIALS trial_result · 2022-10-26Clinical Trial Update: A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer [Phase 2, Phase 3]
Clinical trial update for immunotherapy strategies in metastatic hormone-sensitive prostate cancer (Phase 2/Phase 3).
-
CLINICAL_TRIALS trial_result · 2022-10-24Clinical Trial Update: The Efficacy and Safety of Docetaxel Combined With Platinum for Metastatic Hormone-sensitive Prostate Cancer [Phase 2]
Phase 2 clinical trial update evaluating the efficacy and safety of docetaxel combined with platinum in metastatic hormone-sensitive prostat…